Search Results

« Previous 12345 Next »
Viewing Page 1 of 5 | Showing Results 1 - 10 of 48

BEST-CLI: RANDOMIZED, MULTICENTER, CONTROLLED TRIAL TO COMPARE BEST ENDOVASCULAR VERSUS BEST SURGICAL THERAPY IN PATIENTS WITH CRITICAL LIMB ISCHEMIA

To compare and evaluate the effectiveness of best endovascular compared to best surgical revascularization in patients with Critical Limb Ischemia.

P. Gregory Hayes, MD

REPRISE III: REPOSITIONABLE PERCUTANEOUS REPLACEMENT OF STENOTIC AORTIC VALVE THROUGH IMPLANTATION OF LOTUS VALVE SYSTEM - RANDOMIZED CLINICAL TRIAL EVALUATION

To evaluate the safety and effectiveness of the Lotus Valve System for transcatheter aortic valve replacement (TAVR) in symptomatic subjects with...

Ming Zhang, MD, PhD

CAROTID REVASCULARIZATION AND MEDICAL MANAGEMENT FOR ASYMPTOMATIC CAROTID STENOSIS TRIAL (CREST-2)

CREST-2 is two parallel endpoint clinical trials: one trial will assess treatment differences between intensive medical management alone compared...

Robert Bersin, MD

The Global cVAD Registry Protocol

The goal of the Global cVAD Registry is to collect clinical and procedural data retrospectively from hospital medical records for patients who...

John L. Petersen II, MD

EVOLVE Short DAPT

The EVOLVE Short DAPT Study is a prospective, multicenter, single-arm study designed to assess the safety of 3-month DAPT in subjects at high risk...

SHIELD II - Supporting Patient Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device

The HeartMate PHP System is a temporary (<6 hours) ventricular assist device indicated for use during high risk percutaneous coronary...

John L. Petersen II, MD

DECAAF II - Efficacy of DE-MRI-Guided Fibrosis Ablation vs. Conventional Ablation of Atrial Fibrillation

To examine the efficacy of targeting atrial fibrosis tissue during an ablation procedure treating persistent Atrial Fibrillation.

Darryl S. Wells, MD

Medtronic TAVR Low Risk

Evaluating the safety and effectiveness of the Medtronic TAVR (Transcatheter Aortic Valve Replacement) System in patients with severe aortic...

Sameer Gafoor, MD and Eric Lehr, MD

AMPLATZER AMULET Left Atrial Appendage Occluder Randomized Controlled Trial

The AmuletTM device will be evaluated for safety and efficacy by demonstrating its performance is non-inferior to the commercially available WATCHMAN® left atrial appendage closure device in patients with non-valvular atrial fibrillation.  Patients who are eligible for the trial will be randomized to receive either the Amulet device or the WATCHMAN device and will be followed for 5 years after device implant.

Sameer Gafoor, MD
« Previous 12345 Next »
Viewing Page 1 of 5 | Showing Results 1 - 10 of 48